Andrew Huberman — Professor of neurobiology and ophthalmology at Stanford School of Medicine and host of the Huberman Lab podcast. This is a solo episode.
The gist
Andrew Huberman delivers a solo deep-dive on MDMA (ecstasy), explaining its unusual chemistry as a synthetic compound that powerfully raises both dopamine and serotonin, acting as an empathogen rather than a classic psychedelic. He walks through how MDMA reduces amygdala-insula threat connectivity, why this makes it valuable for PTSD, and how its effects differ from psilocybin, LSD, and ketamine. He carefully examines the neurotoxicity debate, including a retracted Science paper, the role of caffeine, body temperature, and fentanyl contamination of street supply. He closes with the MAPS Phase 3 clinical trial results showing MDMA-assisted therapy achieving roughly 88% clinical response and 67% PTSD remission, far exceeding talk therapy plus placebo.
Big reveals
- MDMA was first synthesized by drug company Merck in the early 1900s but was never applied to a clinical use until rediscovered by chemist Alexander Shulgin.
- MDMA raises serotonin at least three times and maybe up to eight times more than it raises dopamine, an unusual combination unique among compounds.
- Unlike psilocybin and LSD which act on the serotonin 2A receptor, MDMA largely acts on the serotonin 1B receptor, explaining its distinct pro-social effects.
- Despite huge oxytocin increases from MDMA, the data show oxytocin is NOT the source of its pro-social effects.
- The famous 2002 Science paper claiming MDMA causes severe primate neurotoxicity was retracted; the monkeys were accidentally given methamphetamine, not MDMA.
- MDMA-assisted therapy achieved an 88% clinically effective response versus 60% for therapy plus placebo, with 67% no longer meeting PTSD criteria.
- Internet 5-HTP/L-tryptophan/L-tyrosine 'crash' protocols are likely useless or even detrimental; the crash is better explained by a rise in prolactin.
Things worth remembering
- MDMA is a purely synthetic compound that, as far as we know, does not exist anywhere in nature, unlike mescaline, LSD precursors, or psilocybin.
- A Johns Hopkins study found octopuses given MDMA spend more time socializing, and their serotonin transporter shares homology with humans'.
- Typical study dosages of MDMA range from 0.75 to 1.5 milligrams per kilogram of body weight.
- MDMA at 1.5 mg/kg raised circulating oxytocin nearly five-fold, from 18.6 to 83.7 picograms per milliliter.
- Even a single dose of methamphetamine can be neurotoxic, and combining caffeine with amphetamines or MDMA increases that neurotoxicity.
- An increase of just three or four degrees in body temperature can start to kill neurons, making hot rave environments a real neurotoxicity risk.
- An estimated 60 to 80 percent of gray-market drugs are repackaged with deadly fentanyl, making street MDMA sourcing extremely dangerous.
- As many as eight percent of people in the United States have PTSD, with high comorbidity rates for addiction and depression.
- About half of people who do talk therapy alone for PTSD achieve no long-lasting relief of symptoms.
Recommended in this episode
Books, products and media the guest or host genuinely endorsed here — with the buy link.
Affiliate link — we may earn a commission at no extra cost to you.
Trauma: The Invisible Epidemic
Paul Conti
“if any of you are interested in trauma and its treatment I highly recommend the book trauma by Dr Paul Conte he's an MD medical doctor psychiatrist” — Andrew Huberman 01:44:22Find it on Amazon